Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1179-1190

  Akli, Said ^a   Bui, Tuyen ^a   Wingate, Hannah ^a   Biernacka, Anna ^a   Moulder, Stacy ^b   Tucker, Susan L ^b   Hunt, Kelly K ^b   Keyomarsi, Khandan ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROTEIN P27; ROSCOVITINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG INHIBITION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN E; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE; HUMANS; MOLECULAR WEIGHT; NITRILES; POSTMENOPAUSE; PROGNOSIS; PURINES; TRIAZOLES;

EID: 76749155560     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1787     Document Type: Article

References (35)

1. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
2. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70.
3. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of theATACtrial. Lancet Oncol 2008;9:45-53.
4. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007;105 Suppl 1:33-43.
5. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
6. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569-75.
7. Normanno N, Di Maio M, De Maio E, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12:721-47.
8. Generali D, Buffa FM, Berruti A, et al. Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009;27:227-34.
9. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003;2:S38-47.
10. Akli S, Zheng PJ, MultaniAS, et al.Tumor-specific lowmolecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208.
11. 1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-cdk2 and cyclin D1-2 complexes. Proc Natl Acad Sci U S A 1993;90:11034-8.
12. Spruck CH, Won K-A, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
13. Keyomarsi K, Conte D, Jr., Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941-50.
14. Sgambato A, Han EK, Zhou P, Schieren I, Weinstein IB. Overexpression of cyclin E in the HC11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27 (Kip1). Cancer Res 1996;56:1389-99.
15. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003;22:4898-904.
16. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
17. Kaplan EP, Meier P. Nonparametric estimation of incomplete observatons. J Am Stat Assoc 1958;53:457-81.
18. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34: 187-220.
19. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54.
20. Colomer R, Monzo M, Tusquets I, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-6.
21. Kuske B, Naughton C, Moore K, et al. Endocrine therapy resistance can be associated with high estrogen receptor α (ERα) expression and reduced ERá phosphorylation in breast cancer models. Endocr Relat Cancer 2006;13:1121-33.
22. Masri S, Phung S, Wang X, et al. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-termestrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008;68:4910-8.
23. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009;69:1416-28.
24. Lisztwan J, Pornon A, Chen B, Chen S, Evans DB. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogendependent breast cancer. Breast Cancer Res 2008;10:R56.
25. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-8.
26. Porter DC, Zhang N, Danes C, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21:6254-69.
27. Bales E, Mills L, Milam N, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005;65:692-7.
28. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004;23:2648-57.
29. Corin I, Di Giacomo MC, Lastella P, Bagnulo R, Guanti G, Simone C. Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors. Cancer Biol Ther 2006;5:198-203.
30. Davidson B, Skrede M, Silins I, Shih Ie M, Trope CG, Florenes VA. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 2007;110:1264-71.
31. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112-6.
32. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2003;2:461-6.
33. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 2005;280:15148-57.
34. Akli S, Van Pelt CS, Bui T, et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 2007;67:7212-22.
35. Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002;21:4626-34.